Stereotactic Radiotherapy for Wet AMD (STAR)

Prior treatment

• Prior or current therapies in the study eye for age-related macular degeneration, other than anti-VEGF agents, including submacular surgery, subfoveal thermal laser photocoagulation, photodynamic therapy (PDT), or transpupillary thermotherapy (TTT).
• Previous radiation therapy to the study eye, head, or neck with the exception of radio-iodine treatment for hyperthyroidism, epimacular brachytherapy to the non-study eye, or Oraya SRT to the non-study eye.
• Intraocular surgery or laser-assisted in situ keratomileusis (LASIK) in the study eye within 12 weeks prior to enrolment.
• Prior pars plana vitrectomy in the study eye.
• Women who are pregnant at the time of radiotherapy.
• Participants with an implantable cardioverter defibrillator (ICD) or pacemaker implant (or any implanted device) where the device labelling specifically contraindicates patients undergoing X-ray.

Other illness

• Type 1 or Type 2 diabetes mellitus.
• Study eyes with CNV due to causes other than AMD, including presumed ocular histoplasmosis syndrome (POH), angioid streaks, multifocal choroiditis, choroidal rupture, and pathological myopia (greater than 8 Dioptres spherical equivalent). Participants with retinal angiomatous proliferation (RAP) or idiopathic polypoidal choroidal vasculopathy (IPCV) are not excluded.
• Known allergy to intravenous fluorescein, ICG or intravitreal ranibizumab.
• Any other condition, which in the judgment of the investigator, would prevent the participant from granting informed consent or completing the study, such as dementia, and mental illness (including generalized anxiety disorder and claustrophobia).

Other

• Disciform scarring that involves the fovea, in the study eye.
• Visual acuity worse than 6/96 (24 ETDRS letters) in the study eye.
• Lesion size greater than 4 mm in greatest linear dimension, or greater than 2 mm from the centre of the fovea to the furthest point on the lesion perimeter.
• An axial length of less than 20 mm, or greater than 26 mm, in the study eye.
• Contraindication or sensitivity to contact lens application, including recurrent corneal erosions, in the study eye.
• Retinopathy in the study eye.
• Presence of an intravitreal device in the study eye.
• Inadequate pupillary dilation or significant media opacities in the study eye, including cataract, which may interfere with visual acuity testing, the clinical evaluation of the posterior segment, or fundus imaging.
• Current participation in another interventional clinical trial, or participation in such a clinical trial within the last six months.
• Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial.

• Participants must have neovascular AMD in the study eye, for which they have received at least 3 prior intravitreal injections of either bevacizumab (Avastin), aflibercept (Eylea), ranibizumab (Lucentis), or pegaptanib (Macugen).
• Participants must have received an anti-VEGF injection in the study eye within 3 months prior to enrolment.
• Participants must require treatment with anti-VEGF therapy at the time of enrolment, due to OCT evidence of subretinal fluid and/or cystoid macular oedema, and have a macular volume that is greater than the 95th percentile of normal for the SD-OCT machines used in the investigational sites.
• Participants must be at least 50 years of age.